Reckitt Benckiser
RB to pay over $2 billion in opioids case
To resolve potential criminal liability stemming from conduct alleged in the indictment of a former subsidiary in the United States, RB Group will forfeit nearly one billion in proceeds and …
RB loses final Nurofen appeal in High Court
It must pay the $6 million penalty for making misleading representations about its Nurofen Specific Pain products A final High Court appeal by Reckitt Benckiser against a penalty imposed for …
Record fine for RB over Nurofen Specific Pain range
Reckitt Benckiser has been given a record fine for making misleading representations about its Nurofen Specific Pain range The Full Federal Court has upheld an appeal by the Australian Competition …
ACCC appeals $1.7m Nurofen penalty
Consumer watchdog says fine is inadequate deterrent. The Australian Competition and Consumer Commission (ACCC) is appealing the federal court’s decision to fine Reckitt Benckiser $1.7 million for its Nurofen Specific Pain …
RB launches more GORD training
Reckitt Benckiser has launched part two of the GORD Matters CPD accredited training program for pharmacists. The GORD Matters 2 module is designed to assist pharmacists gain a greater understanding …